COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax : a single-center observational cohort study. / Thau, Sophie; Poulsen, Christian Bjørn; Brieghel, Christian; Larsen, Morten Kranker; Wiese, Lothar; Nielsen, Xiaohui Chen; Pedersen, Lars Møller.
I: Annals of Hematology, 2024.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax
T2 - a single-center observational cohort study
AU - Thau, Sophie
AU - Poulsen, Christian Bjørn
AU - Brieghel, Christian
AU - Larsen, Morten Kranker
AU - Wiese, Lothar
AU - Nielsen, Xiaohui Chen
AU - Pedersen, Lars Møller
N1 - Publisher Copyright: © The Author(s) 2024.
PY - 2024
Y1 - 2024
N2 - Patients with chronic lymphocytic leukemia (CLL) are at high risk of developing severe COVID-19. The present study was undertaken to elucidate COVID-19 related morbidity and mortality in CLL patients treated with venetoclax. We present a single-center study of 108 patients with small lymphocytic lymphoma or CLL treated with venetoclax. Primary outcome was 30-day COVID-19 mortality. Secondary outcomes included COVID-19 severity and hospitalization rate. Forty-eight (44%) patients had PCR-verified SARS-COV-2 between March 2020 and January 2023. Thirty-six patients (75%) presented with asymptomatic/mild COVID-19 and 12 (25%) with severe/critical disease. The hospitalization rate was 46% with a 30-day mortality rate of only 4% and severe comorbidities as the primary cause of death. COVID-19 severity and mortality were similar before and during the Omicron era. High CIRS-scores (P < 0.02) and thrombocytopenia (P < 0.01) were more frequent in patients with severe/critical disease. In real-world data, most venetoclax treated patients presented with mild COVID-19. Hospitalization and mortality rates were low compared to data of general CLL populations. Our data indicate that venetoclax was a safe treatment option for CLL patients during the pandemic.
AB - Patients with chronic lymphocytic leukemia (CLL) are at high risk of developing severe COVID-19. The present study was undertaken to elucidate COVID-19 related morbidity and mortality in CLL patients treated with venetoclax. We present a single-center study of 108 patients with small lymphocytic lymphoma or CLL treated with venetoclax. Primary outcome was 30-day COVID-19 mortality. Secondary outcomes included COVID-19 severity and hospitalization rate. Forty-eight (44%) patients had PCR-verified SARS-COV-2 between March 2020 and January 2023. Thirty-six patients (75%) presented with asymptomatic/mild COVID-19 and 12 (25%) with severe/critical disease. The hospitalization rate was 46% with a 30-day mortality rate of only 4% and severe comorbidities as the primary cause of death. COVID-19 severity and mortality were similar before and during the Omicron era. High CIRS-scores (P < 0.02) and thrombocytopenia (P < 0.01) were more frequent in patients with severe/critical disease. In real-world data, most venetoclax treated patients presented with mild COVID-19. Hospitalization and mortality rates were low compared to data of general CLL populations. Our data indicate that venetoclax was a safe treatment option for CLL patients during the pandemic.
KW - CLL (chronic lymphocytic leukemia)
KW - COVID-19
KW - Small lymphocytic lymphoma
KW - Venetoclax
UR - http://www.scopus.com/inward/record.url?scp=85190660584&partnerID=8YFLogxK
U2 - 10.1007/s00277-024-05738-4
DO - 10.1007/s00277-024-05738-4
M3 - Journal article
C2 - 38634916
AN - SCOPUS:85190660584
JO - Revue d'hématologie
JF - Revue d'hématologie
SN - 0945-8077
ER -
ID: 390576822